Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis
Our study underscores the pivotal role of CHIT1 in MASH. The observed significant improvement in inflammation and hepatic fibrosis, particularly at higher doses of the CHIT1 inhibitor, strongly suggests the potential of CHIT1 as a therapeutic target in MASH accompanied by progressive liver fibrosis.
Authors
- Na Ri Park (ORCID: https://orcid.org/0000-0003-0297-4522)
- Jung Hoon (ORCID: https://orcid.org/0000-0001-7499-8377)
- Pil Soo Sung (ORCID: https://orcid.org/0000-0002-5780-9607)
- Si Hyun Bae (ORCID: https://orcid.org/0000-0003-1727-7842)
- Jeong Won Jang (ORCID: https://orcid.org/0000-0003-3255-8474)
- Seung Kew Yoon (ORCID: https://orcid.org/0000-0002-4476-4868)
- Hyun Yang (ORCID: https://orcid.org/0000-0001-6588-9806)
- Jong Young Choi (ORCID: https://orcid.org/0000-0001-7833-0307)
- Heechul Nam (ORCID: https://orcid.org/0000-0001-5421-6868)
- Eun Sun Jung (ORCID: https://orcid.org/0000-0002-8451-939X)
- Sung Woo Cho
Institutions
- St. Mary's Hospital (US)
- The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR)
- St. Mary's Hospital (US)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.3389/fimmu.2024.1444100
- Citations
- 3
- Primary Topic
- Pancreatitis Pathology and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.72